Despite the Market Crash, These Stocks Are at Their All-Time Highs
Parth DSIJ / 04 Mar 2026 / Categories: Mindshare, Trending
Despite market downturns and ongoing wars, Sundaram Finance Ltd and Sai Life Sciences Ltd have reached record highs, driven by strategic growth initiatives and sound quarterly performance.
The conflict between the USA–Israel alliance and Iran has entered its fifth day as of Wednesday, March 4, 2026. What began as a series of targeted strikes on February 28 has evolved into a multi-front regional war with severe implications for global energy and the Indian economy. The military actions that have occurred in the last five days have sent shock waves throughout the world and affected the stock markets globally.
In India, on March 4, 2026, the markets closed with the NIFTY 50 at 24,480, down 1.55 per cent, and the BSE Sensex at 79,116.19, down 1.40 per cent. All the major indices closed in the red.
Despite this, two stocks have emerged stronger and recorded their all-time highs -
Sundaram Finance is a registered deposit-taking NBFC established in 1954. Started with the primary objective of financing the purchase of commercial vehicles, the company has today grown into one of the most trusted financial services groups in India. Today, Sundaram Finance Limited has a diversified presence in Mutual Funds, Housing Finance, General Insurance, IT, Business Process Outsourcing, and Retail Distribution of a wide array of financial services and products.
The company has made its all-time high on March 04, 2026, reaching Rs 5,642 in the day and closing at Rs 5,440, growing at 2.62 per cent as compared to the previous day.
CY 2026 Returns: Sundaram Finance Ltd has delivered a YTD return of +1.29 per cent in calendar year 2026.
Company Updates -
On November 11, 2025, the company has announced a strategic partnership with Citroën India. This partnership has been made to make Citroën vehicles and financing solutions more accessible for customers nationwide. This collaboration is a key pillar of Citroën’s ‘Citroën 2.0 – Shift into the New’ strategy, focused on delivering seamless, customer-first ownership experiences.
As of December 31, 2026, the company has reported an AUM of Rs 58, 263 crore, up by 16 per cent from December 2024.
Disbursements for Q3 2025-26 recorded a growth of 14 per cent to Rs 8,847 crore as compared to Rs 7,764 crore registered in Q3 2024-25.
For Q3 2025-26, PAT rose by 15 per cent to Rs 403 crore.
Founded in 1999, Sai Life Sciences is among the largest and fastest-growing integrated CRDMOs listed in India. The company is a fully integrated, science-led contract research, development, and manufacturing organisation (CRDMO) focused on small molecule new chemical entities (NCEs).
The company reached an all-time high of Rs 1,015 on March 4, 2026, and closed the day at Rs 1,004.30, marking a 0.80 per cent increase from the previous day.
CY 2026 Returns: Sai Life Sciences Ltd has delivered a YTD return of +11.52 per cent in calendar year 2026.
Company Updates -
The global macro environment continues to be supportive of the industry, with India increasingly positioned as a preferred destination for pharmaceutical outsourcing. The company is seeing a meaningful rise in strategic conversations with large global pharma innovators, driven by their focus on supply chain resilience, access to specialised capabilities, and long-term partnerships.
The company is expecting sustained growth momentum led by a clear focus on expanding engagements with large pharma customers. In parallel, the company is strengthening its discovery engine through targeted investments in next-generation technologies that accelerate speed and productivity, such as AI-based retrosynthesis tools, advanced photochemical and electrochemical platforms, and partnerships with emerging technology innovators.
Revenue for Q3 2025-26 was Rs 556 crore, a 27 per cent increase over Rs 440 crore in Q3 2024-25, driven by strong growth both in CRO and CDMO services.
EBITDA for Q3 2025-26 stood at Rs 191 crore compared to Rs 124 crore in Q3 2024-25, an increase of 54 per cent. PAT for Q3 2025-26 increased to Rs 100 crore, registering a growth of 86 per cent Y-o-Y as compared to Rs 54 crore in Q3 2024-25.
Disclaimer: The article is for informational purposes only and not investment advice.